Oncolys BioPharma Inc.
TSE:4588.T
694 (JPY) • At close March 11, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) JPY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 31.384 | 63.038 | 976.182 | 642.494 | 314.179 | 1,303.844 | 168.549 | 229.139 | 178.313 | 121.303 | 28.797 | 1.18 | 396.754 |
| Cost of Revenue
| 0 | 32.433 | 637.695 | 443.69 | 78.065 | 112.9 | 121.331 | 71.557 | 0.016 | 0.016 | 0.394 | 0.04 | 0 |
| Gross Profit
| 31.384 | 30.605 | 338.487 | 198.804 | 236.114 | 1,190.944 | 47.218 | 157.582 | 178.297 | 121.287 | 28.403 | 1.14 | 396.754 |
| Gross Profit Ratio
| 1 | 0.486 | 0.347 | 0.309 | 0.752 | 0.913 | 0.28 | 0.688 | 1 | 1 | 0.986 | 0.966 | 1 |
| Reseach & Development Expenses
| 1,088.997 | 1,351.94 | 947.491 | 825.474 | 987.242 | 562.694 | 605.822 | 570.541 | 360.869 | 552.741 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 1,718.992 | 0 | 574.64 | 725.938 | 877.984 | 1,072.614 | 625.402 | 599.115 | 663.017 | 502.999 | 0 | 0 | 0 |
| Other Expenses
| -1,095.202 | 608.651 | 1,542.993 | 1,653.357 | 1,910.766 | 1,702.406 | 0.03 | 0.029 | 0.303 | 99.008 | 98.05 | 39.587 | 2.91 |
| Operating Expenses
| 1,712.787 | 1,960.591 | 1,542.993 | 1,653.357 | 1,910.766 | 1,702.406 | 1,294.781 | 1,235.97 | 1,039.608 | 1,072.862 | 856.148 | 666.601 | 537.709 |
| Operating Income
| -1,681.403 | -1,929.986 | -1,204.506 | -1,454.554 | -1,674.653 | -511.463 | -1,247.563 | -1,078.389 | -861.311 | -951.575 | -827.744 | -665.462 | -140.954 |
| Operating Income Ratio
| -53.575 | -30.616 | -1.234 | -2.264 | -5.33 | -0.392 | -7.402 | -4.706 | -4.83 | -7.845 | -28.744 | -563.951 | -0.355 |
| Total Other Income Expenses Net
| 0.388 | -5.592 | 58.501 | -157.16 | -416.707 | -397.13 | 17.458 | -8.796 | -67.033 | 96.874 | 90.638 | 32.269 | 40.441 |
| Income Before Tax
| -1,681.015 | -1,935.578 | -1,146.005 | -1,611.714 | -2,091.359 | -908.593 | -1,230.105 | -1,087.185 | -928.344 | -854.701 | -737.106 | -633.193 | -100.513 |
| Income Before Tax Ratio
| -53.563 | -30.705 | -1.174 | -2.509 | -6.657 | -0.697 | -7.298 | -4.745 | -5.206 | -7.046 | -25.597 | -536.604 | -0.253 |
| Income Tax Expense
| 3.763 | 2.926 | 2.932 | 3.725 | 3.727 | 3.752 | 3.74 | 3.518 | 3.052 | 2.588 | 1.892 | 2.359 | 2.315 |
| Net Income
| -1,684.778 | -1,938.505 | -1,148.937 | -1,615.439 | -2,095.086 | -912.345 | -1,233.846 | -1,090.703 | -931.397 | -857.29 | -738.999 | -635.553 | -102.829 |
| Net Income Ratio
| -53.683 | -30.751 | -1.177 | -2.514 | -6.668 | -0.7 | -7.32 | -4.76 | -5.223 | -7.067 | -25.662 | -538.604 | -0.259 |
| EPS
| -77.17 | -108.92 | -66.31 | -95.5 | -145.58 | -65.55 | -104.55 | -106.23 | -101.18 | -93.35 | -80.55 | -94.33 | -16.83 |
| EPS Diluted
| -77.17 | -108.92 | -66.31 | -95.5 | -145.58 | -65.55 | -104.55 | -106.23 | -101.18 | -93.35 | -80.55 | -94.33 | -16.83 |
| EBITDA
| -1,686.793 | -1,929.691 | -1,141.146 | -1,601.058 | -2,082.295 | -901.535 | -1,225.242 | -1,082.389 | -909.4 | -833.335 | -716.278 | -613.215 | -75.215 |
| EBITDA Ratio
| -53.747 | -30.612 | -1.186 | -2.319 | -5.457 | -0.408 | -7.271 | -4.725 | -4.735 | -6.873 | -24.606 | -512.986 | -0.185 |